



Date: August 11th, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

To,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai 400 051

Scrip Code: 503162

Trading Symbol: RELCHEMQ

Dear Sir/Madam,

Sub.: - Unaudited Financial Results for the quarter ended June 30, 2026

Pursuant to Regulations 30, 33 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of Reliance Chemotex Industries Ltd. ('the Company') at their meeting held today i.e. August 11, 2026, through video conferencing, which commenced at 11:45 A.M. and concluded at 12:30 P.M., inter alia transacted the following business:-

1. Approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026 and took on record Limited Review Report thereon. (Enclosed herewith as Annexure-1);

The extract of financial results would also be published in the newspapers in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prohibition of Insider Trading, the "Trading Window" for trading in the shares of the Company shall remain closed till August 13, 2026 for the Designated Persons of the Company and their immediate relatives.

Kindly take the above information on record.

Thanking You,

For Reliance Chemotex Industries Ltd.

Chandrasekaran Rajagopalan
CFO cum Company Secretary and Compliance Officer
M.No.: A12420

Encl: as above

Limited Review Report on Quarterly Unaudited Financial Results of Reliance Chemotex Industries Limited for the quarter ended 30th June 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**Board of Director of
Reliance Chemotex Industries Limited**

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Reliance Chemotex Industries Limited** ("the Company") for the quarter ended 30th June 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This Statement, which is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditors of the Entity*", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 11th August 2026



For **P K M B & Co.**
Chartered Accountants
(Firm Registration No. 005311 N)

P.K. Jain
(P.K. Jain)
Partner

Membership No. 010479
UDIN: 26010479NIVGDX3746



**RELIANCE
CHEMOTEX**
INDUSTRIES LIMITED

RELIANCE CHEMOTEX INDUSTRIES LIMITED

Regd. Office: Village Kanpur, Post Box No. 73, Udaipur, Rajasthan -313003

CIN: L40102RJ1977PLC001994

Telephone No: 0294-2490488, Fax No: 0294-2490067

Email: finance@reliancechemotex.com; Website: www.reliancechemotex.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

RS. IN LACS EXCEPT EPS

Sl. No.	Particulars	Quarter ended 30.06.2026 (Un-Audited)	Quarter ended 30.06.2025 (Un-Audited)	Quarter ended 31.03.2026 (Audited) (Refer Note 3)	Year ended 31.03.2026 (Audited)
1	Income				
	(a) Revenue from operation	9,881.78	9,236.37	8,817.66	36,200.58
	(b) Other Income	89.73	39.05	267.71	382.94
	Total Income (a+b)	9,971.51	9,275.42	9,085.37	36,583.52
2	Expenses				
	(a) Cost of Raw Materials Consumed	5,413.00	4,634.50	4,880.63	18,798.12
	(b) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-trade, etc.	(805.10)	(257.58)	(1,255.15)	(2,606.43)
	(c) Employee Benefits Expense	1,714.83	1,658.30	1,754.68	6,774.57
	(d) Finance Cost	676.45	649.77	621.10	2,490.48
	(e) Depreciation and Amortization Expense	363.46	369.32	370.26	1,479.24
	(f) Power & fuel	1,172.21	1,057.93	1,195.12	4,607.51
	(g) Other Expenses	1,306.68	1,067.67	1,344.88	4,555.98
	Total Expenses	9,841.53	9,179.91	8,911.52	36,099.47
3	Profit Before Tax (1-2)	129.98	95.51	173.85	484.05
4	Tax Expense				
	Current tax	-	17.00	62.00	94.50
	MAT Credit Entitlement	-	(16.75)	(61.73)	(93.75)
	Tax for earlier year	-	-	-	6.45
	Deferred Tax	(6.67)	(11.07)	(1.01)	(49.30)
5	Net Profit for the Period (3-4)	136.65	106.33	174.59	526.15
6	Other Comprehensive Income				
	Items that will not be re classified to Profit and Loss				
	i) Re-imbursement (gain/Loss) on defined benefit plan	19.41	11.88	(40.68)	77.64
	ii) Tax on (i) above	(5.05)	(3.31)	11.23	(19.53)
7	Total Comprehensive Income for the Period (5+6)	151.01	114.90	145.14	584.26
8	Paid-up Equity Share Capital (Face value of Rs.10/- per Share)	754.36	754.36	754.36	754.36
9	Other Equity				13,518.88
10	Basic & Diluted EPS (Rs.) (not annualised)	1.81	1.41	2.31	6.97

Notes:

- The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th August 2026.
- The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices to the extent applicable.
- The figures for the quarter ended March 31, 2026 are the balancing figure between audited figures in respect of full Financials year ended March 31, 2026 and the published unaudited year to date figures upto December 31, 2025 subject to limited review.
- The Company has only one reportable primary business segment i.e. Yarns.

For and on behalf of the Board of Directors

Sanjiv Shroff
(Managing Director)
DIN: 00296008

Date : 11/08/2026
Place : Mumbai

Corporate Office: 27, Jolly Maker Chambers No. 2, Nariman Point, Mumbai 400021, Maharashtra, India

Phone: +91 22 22028581 / 43420100 **Fax:** +91 22 2045786 **Email:** mumbai@reliancechemotex.com

Registered Office & Manufacturing Unit: Village Kanpur, Post Box No. 73, Udaipur 313003, Rajasthan, India

CIN: L40102RJ1977PLC001994